Advertisement

Topics

Alector LLC Company Profile

01:01 EDT 23rd October 2018 | BioPortfolio

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams. For more information, contact info@alector.com. www.alector.com


News Articles [21 Associated News Articles listed on BioPortfolio]

Alector raises $133m to advance Alzheimer’s disease drugs

Biotechnology firm Alector has raised $133m in a series E financing round to support further development of its clinical programmes...Read More... The post Alector raises $133m to advance Alzheimer’...

Alector starts Phase l trial of AL001 for frontotemporal dementia

Alector has commenced a Phase l INFRONT trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 for the...Read More... The post Alector starts Phase l trial of A...

Biotech startup Alector raises $133M

Alector, a biotech startup working on treatments for neurodegenerative disorders, including Alzheimer's, raised $133 million  -More- 

Alector Closes $133 Million to Expand Alzheimer’s Programs

South San Francisco-based Alector closed on a Series E financing worth $133 million. The money will be used to advance the company’s clinical programs and expand its discovery platform.

Alector Snags $133M to Activate Immune Cells Against Neurodegeneration

Pharmaceutical companies have been working for years to find a drug that could break up the toxic clusters of proteins associated with Alzheimer’s disease and other neurodegenerative disorders. Many...

Alector closes $133mm Series E round

Alector Inc. (immuno-neurology and immuno-oncology) raised $133mm through its Series E round from a large syndicate of investors including Deerfield Management, AbbVie Ventures, Federated Kaufmann Fun...

Alector announces initiation of Phase 1 trial of AL001 for treating frontotemporal dementia

Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of its Phase 1 trial ca...

Alector raises $133M series E

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Alector LLC

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, ...

Alector, Inc.

Alector is a privately owned biotechnology company whose mission is to develop therapies that harness the immune system to treat neurodegenerative diseases and cancer. Alector was...

More Information about "Alector LLC" on BioPortfolio

We have published hundreds of Alector LLC news stories on BioPortfolio along with dozens of Alector LLC Clinical Trials and PubMed Articles about Alector LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alector LLC Companies in our database. You can also find out about relevant Alector LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...


Corporate Database Quicklinks



Searches Linking to this Company Record